Modulating the CX3CL1/CX3CR1 axis, perhaps through the sFKN supplementation or small-molecule CX3CR1 agonists/positive allosteric modulators of CX3CR1 signaling, could offer a novel strategy for treating various forms of SNHL where macrophage activity and neuronal or synaptic damage are key features. Here, CX3CR1 is linked to sensorineural hearing loss disorder.